Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
Open accessAbstract
BACKGROUND: Mangiferin (MNG) is known to possess antidiabetic and antioxidant activity. However, there is no experimental evidence presently available in the literature with regard to its ameliorating effects on diabetes mellitus coexisting with metabolic syndrome. OBJECTIVE: The present study was designed to evaluate the protective effects of MNG on various components of metabolic syndrome with diabetes as an essential component. MATERIAL AND METHODS: Adult Wistar rats were fed high-fat diets for 10 weeks and challenged with streptozotocin (40 mg/kg) at week three (high-fat diabetic control group). After the confirmation of metabolic syndrome in the setting of diabetes, MNG 40 mg/kg was orally fed to these rats from the fourth to tenth week. RESULTS: The treatment with MNG showed beneficial effects on various components of metabolic syndrome, such as reduced dyslipidemia (decreased triglyceride, total cholesterol, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol) and diabetes mellitus (reduced blood glucose and glycosylated hemoglobin). In addition, an increase in serum insulin, C-peptide, and homeostasis model assessment-β and a reduction in homeostasis model assessment of insulin resistance-IR were observed in MNG-treated group compared with high-fat diabetic control group. MNG was also found to be cardioprotective (reduction in creatine phosphokinase-MB levels, atherogenic index, high-sensitivity C-reactive protein). Reduction in serum dipeptidyl peptidase-IV levels in the MNG-treated group correlated with improvement in insulin resistance and enhanced β-cell function. CONCLUSION: The present study has demonstrated antidiabetic, hypolipidemic, and cardioprotective effects of MNG in the setting of diabetes with metabolic syndrome. Thus, MNG has the potential to be developed as a natural alternative to synthetic dipeptidyl peptidase-IV inhibitors beneficial in this comorbid condition.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mangiferin exerts significant antidiabetic, antihyperlipidemic and antiatherogenic effects in diabetic rat models.
“Similarly, Muruganandan et al (28), Miura et al (29,30) and Suman et al (31) verified that mangiferin exerted significant antidiabetic, antihyperlipidemic and antiatherogenic effects in diabetic rat models.”
From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
Antihyperglycemic effect of mangiferin in streptozotocin induced diabetic rats
Sellamuthu, P. S., Muniappan, B. P., Perumal, S. M., & Kandasamy, M. (2009) · Journal of Health Science · doi:10.1248/jhs.55.206 · Cited by 122 · see citing works
Flagged first, then by citations
Research works printed but not linked: 16
- [1]Huang PL A comprehensive definition for metabolic syndrome Dis Model Mech 2009 2 231 237 19407331 PMC2675814
- [2]Matteucci E Giampietro O Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety Curr Med Chem 2011 18 31 4753 4760 21919850
- [3]Nicolau Ramis J Masmiquel Comas L The new antidiabetic agents in firing line. Safety reason or witch hunt Endocrinol Nutr 2012 59 1 1 8 22177885
- [4]Monami M Dicembrini I Mannucci E Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials Diabetes Obes Metab 2014 16 48 56 23837679
- [5]Elashoff M Matveyenko AV Gier B Elashoff R Butler PC Pancreatitis and thyroid cancer with glucagon like peptide-1-based therapies Gasteroenterology 2011 141 150 156 PMC4404515 21334333
- [6]Muruganandan S Srinivasan K Gupta S Gupta PK Lal J Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats J Ethnopharmacol 2005 97 497 501 15740886
- [7]Andreu GP Delgado R Velho JA Curti C Vercesi AE Iron complexing activity of mangiferin, a naturally occurring glucosylxanthone, inhibits mitochondrial lipid peroxidation induced by Fe(2)-citrate Eur J Pharmacol 2005 513 47 53 15878708
- [8]Aderibigbe AO Emudianughe TS Lawal BA Evaluation of antidiabetic action of Mangifera indica in mice Phytother Res 2001 15 456 458 11507745
- [9]Aderibigbe AO Emudianughe TS Lawal BA Antihyperglycemic effect of Mangifera indica in rats Phytother Res 1999 13 504 507 10479762
- [10]Saleh S El-Maraghy N Reda E Barakat W Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: role of adiponectin and TNF-α An Acad Bras Cienc 2014 86 4 1935 1948 25590730
- [14]Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the Natural Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA 2001 285 2486 2497 11368702
- [15]Suman RK Mohanty IR Borde MK Maheshwari U Deshmukh YA Development of an experimental model of diabetes co-existing with metabolic syndrome in rats Adv Pharmacol Sci 2016 2016 9463476 26880906 PMC4736803
- [16]Kuate D Pascale A Kengne N Biapa CPN Azantsa BGK Muda WABW Tetrapleura tetraptera spice attenuates high-carbohydrate, high-fat diet-induced obese and type 2 diabetic rats with metabolic syndrome features Lipids Health Dis 2015 14 50 26003803 PMC4448292
- [18]Randle PJ Garland PB Hales CN Newsholme EA The glucose–fatty acid cycle, its role in insulin sensitivity and metabolic disturbances in diabetes mellitus Lancet 1963 1 785 789 13990765
- [19]Prabhu S Jainu M Sabitha KE Devi CS Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats J Ethnopharmacol 2006 107 126 133 16584858
- [21]Leiro J Arranz JA Yáñez M Ubeira FM Sanmartín ML Orallo F Expression profiles of genes involved in the mouse nuclear factor-kappa B signal transduction pathway are modulated by mangiferin Int Immunopharmacol 2004 4 763 778 15135318
Cited by
Sorted by citations
Mangiferin: An effective therapeutic agent against several disorders (Review)
Du, S., Liu, H., Lei, T., Xie, X., Wang, H., He, X., Tong, R., & Wang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9529 · Cited by 139 · see citing works
“Similarly, Muruganandan et al (28), Miura et al (29,30) and Suman et al (31) verified that mangiferin exerted significant antidiabetic, antihyperlipidemic and antiatherogenic effects in diabetic rat models.”
The management of diabetes mellitus by mangiferin: advances and prospects
Wang, M., Liang, Y., Chen, K., Wang, M., Long, X., Liu, H., Sun, Y., & He, B. (2022) · Nanoscale · doi:10.1039/d1nr06690k · Cited by 56 · see citing works
Suman, R. K., Borde, M. K., Mohanty, I. R., & Singh, H. K. (2023) · International Journal of Applied & Basic Medical Research · doi:10.4103/ijabmr.ijabmr_115_23 · Cited by 7 · see citing works
Self-citation
- Authors
- Suman, R. K., Ray, I., Maheshwari, U., Borde, M. K., & Deshmukh, Y.
- Corresponding author
- Suman, Rajesh Kumar
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-08
- Volume
- Volume 9
- Pages
- 261-272
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC5010077
- OpenAlex
- W2509920538
- Cited by
- 34
- References
- 2
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 1 · 2017: 1
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Indian Council of Medical Research (58/2/2014-BMS)
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- mangiferin, DPP-4 inhibitors, metabolic syndrome, diabetes mellitus, insulin resistance, beta-cell function, hypolipidemic effect, dyslipidemia, cardioprotection, high-fat diet, streptozotocin-induced diabetes, phytochemicals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
